Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors
about
Viral quasispecies evolutionVirological features associated with the development of broadly neutralizing antibodies to HIV-1HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscapeThe genealogical population dynamics of HIV-1 in a large transmission chain: bridging within and among host evolutionary ratesCharacterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionLonger V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virusEvolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding siteLongitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.Cross-reactive broadly neutralizing antibodies: timing is everything.Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virusMultiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanismsHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.HIV-1 evolution in relation to molecular epidemiology and antiretroviral resistance.An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Broadly neutralizing antibodies: An approach to control HIV-1 infection.The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral BurdensEffects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.High-Resolution Sequencing of Viral Populations During Early SIV Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
P2860
Q27013917-25FAB18B-E1DB-485C-A378-192707B9C76AQ27025177-803B1ABB-829E-41FD-BCFF-738D9DBB0A6CQ28487168-99A205D9-F1D6-4D67-BDE0-FA4902A3DA51Q28541827-D5F5A97D-059B-4316-82A8-E6FB3B8BE9B9Q34146374-0BDB4310-F8B3-485E-897E-D4F9F3490AA1Q34645502-E1F78582-9756-48B7-8D5F-1E2C71DC6EDAQ34742533-9C158A78-312C-483D-9FBA-3C80E8FC69A8Q34819651-E72046DD-ECC8-40F5-AA7B-A5338DB2B8BAQ34984724-0B5D881F-6999-4A0A-88F9-32FCC1AE241EQ34990575-5275E000-EE20-4B96-9122-5C913369E2F4Q35076717-0EE59A16-AF6E-4770-95D8-D6A03B92F248Q35077797-6C03F796-25D9-4466-B06B-572AAA7B2A7FQ35109028-1E502AD5-D609-4C9D-9AFF-A0E708981A3DQ35140461-7E1BA468-6A58-41E5-92A0-8191F32142B5Q35192937-D559FE4A-E69A-47E9-95B9-38EF698518ADQ35826458-BC470AEE-8357-4043-9356-DCE1D931A727Q36000736-2DFFD8D1-E216-408E-BDF4-6374C4AF2F45Q36105782-3A4D992E-D162-4DBC-9F57-EFDEB9C8388AQ36249053-E1EF627F-4226-49FD-8833-1EBEBD596423Q36397394-27C53F10-F6E7-421C-8BA7-FBD64FB4D64CQ36760049-E8208827-BBF6-4A5C-9B22-596120CFF8B5Q37073506-592AC6A4-59BE-449F-8752-F87C143AF09FQ37221386-0420F226-2D03-4B8C-B81F-60F93610C36CQ37360774-A8E7B49A-C242-4D66-A40A-7C500D160EA6Q37913478-7A7C0194-C077-43C5-BE46-8C70634FF175Q38283531-1A57C4D9-E15E-4E09-8C2A-DA42B77C55B2Q38811735-667D5CCE-AB14-48F9-A143-2393562D47C9Q40091554-FDD56858-CDF6-4FCF-B06C-A0737C233BDFQ40120996-6F7B4FE5-6DB3-4527-9AFC-68EFD23FCC90Q40568483-BAA3FBD7-635F-4941-91CB-7CA66D4DC086Q40695938-308A0AEE-4B03-4B5D-B652-659F2D35F1C7Q41119832-86219ACD-1132-43F5-B934-BD62ECBE2750Q41876895-D6A5DD31-94EA-4C1B-BE67-E0E6D0C9EFBFQ42726161-74A21ED4-DFFA-4917-8329-284A603B0BBAQ42795407-37848985-26FE-4C72-B435-A174536C06EEQ47110966-1AB5DE6A-42B1-4D5F-AEA1-AD5496D4E545Q47552258-E18AF724-F036-4954-BA81-8281B0CB3899Q56974226-8F70AAC1-EE02-49DB-A5A6-41C26E308E72
P2860
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rapid escape from preserved cr ...... s and long-term nonprogressors
@ast
Rapid escape from preserved cr ...... s and long-term nonprogressors
@en
type
label
Rapid escape from preserved cr ...... s and long-term nonprogressors
@ast
Rapid escape from preserved cr ...... s and long-term nonprogressors
@en
prefLabel
Rapid escape from preserved cr ...... s and long-term nonprogressors
@ast
Rapid escape from preserved cr ...... s and long-term nonprogressors
@en
P2093
P2860
P356
P1433
P1476
Rapid escape from preserved cr ...... s and long-term nonprogressors
@en
P2093
Becky Schweighardt
Hanneke Schuitemaker
Judith A Burger
Terri Wrin
Yodit Jacob
P2860
P304
P356
10.1128/JVI.02622-09
P577
2010-01-13T00:00:00Z